Compare AbbVie Inc (ABBV) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Huntington Ingalls Industries Inc — how do they compare? AbbVie Inc trades at $249.74 (market cap $441.94B), while Huntington Ingalls Industries Inc trades at $324.08 (market cap $12.92B). The key difference: AbbVie Inc is far larger — about 34.2× Huntington Ingalls Industries Inc's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ABBV | HII | |
|---|---|---|
Market Cap | $441.94B | $12.92B |
Sector | Health | Technology |
52-Week High | $263.58 | $453.73 |
52-Week Low | $197.38 | $265.40 |
Enterprise Value | $506.19B | $15.84B |
Dividend Yield | 2.77% | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
HII trades at $324.38, down 1.94% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $5.27, exceeding expectations, and secured a $2.2 billion contract for surveillance capabilities (GlobeNewsWire, August 11, 2026). Valuation ratios include a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook remains positive due to contract wins and margin expansion, but risks include dependence on U.S. defense spending and competitive pressures. The consensus price target of $359.67 suggests upside potential, supported by 44% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
